NC
SAGE

Nexthera Capital’s Sage Therapeutics SAGE Stock Holding History

Nexthera Capital’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-6,200
Closed -$986K – 30
2019
Q1 		$986K Buy
+6,200
New +$898K 1.2% 22
2018
Q3 		– Sell
-79,080
Closed -$12.4M – 63
2018
Q2 		$12.4M Buy
79,080
+853
+1% +$134K 1.92% 16
2018
Q1 		$12.6M Buy
78,227
+22,393
+40% +$3.8M 2.07% 17
2017
Q4 		$9.2M Buy
+55,834
New +$5.41M 1.7% 19

Other funds holding SAGE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Nexthera Capital's SAGE Position: Q2 2019 in Review

Nexthera Capital sold out of Sage Therapeutics (SAGE) in Q2 2019, closing a stake of 6,200 shares — an estimated $986K sold.

Nexthera Capital first reported a position in SAGE in Q4 2017 and held it in 4 quarters. The position peaked at $12.6M in Q1 2018. 272 funds tracked by Wall St. Rank hold SAGE as of Q2 2019.

  • Nexthera Capital reported no remaining Sage Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Nexthera Capital sold 6,200 Sage Therapeutics shares in Q2 2019, an estimated $986K.
  • Nexthera Capital first reported a position in Sage Therapeutics in Q4 2017 and held it in 4 quarters.
  • Nexthera Capital's Sage Therapeutics position peaked at $12.6M in Q1 2018.
  • 272 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2019.

Based on Nexthera Capital's 13F filing for Q2 2019, filed 14 Aug 2019.